Recombinant Anti-Interleukin-9 Antibodies

Abstract

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

1 - 10 . (canceled) 
     
     
         11 . A humanized antibody which specifically binds to human IL-9 comprising at least one CDR with an amino acid sequence with at least 85% sequence identity to any CDR from antibody MH9A3. 
     
     
         12 . The humanized antibody of  claim 11 , wherein the CDR is selected from the group consisting of CDR1, CDR2, and CDR3. 
     
     
         13 . The humanized antibody of  claim 12 , wherein the CDR is in the heavy chain. 
     
     
         14 . The humanized antibody of  claim 13 , wherein the amino acid sequence of CDR1 comprises amino acids 26 to 35 of SEQ ID NO: 3. 
     
     
         15 . The humanized antibody of  claim 13 , wherein the amino acid sequence of CDR1 consists of amino acids 26 to 35 of SEQ ID NO: 3. 
     
     
         16 . The humanized antibody of  claim 13 , wherein the amino acid sequence of CDR2 has at least 90% sequence identity to CDR2 (amino acids 50 to 66 of SEQ ID NO: 3) of MH9A3. 
     
     
         17 . The humanized antibody of  claim 16 , wherein the amino acid sequence of CDR2 comprises amino acids 50 to 66 of SEQ ID NO: 3. 
     
     
         18 . The humanized antibody of  claim 16 , wherein the amino acid sequence of CDR2 consists of amino acids 50 to 66 of SEQ ID NO: 3. 
     
     
         19 . The humanized antibody of  claim 13 , wherein the amino acid sequence of CDR3 has at least 90% sequence identity to CDR3 (amino acids 99 to 111 of SEQ ID NO: 3) of MH9A3. 
     
     
         20 . The humanized antibody of  claim 19 , wherein the amino acid sequence of CDR2 comprises amino acids 99 to 111 of SEQ ID NO: 3. 
     
     
         21 . The humanized antibody of  claim 19 , wherein the amino acid sequence of CDR2 consists of amino acids 99 to 111 of SEQ ID NO: 3. 
     
     
         22 . The humanized antibody of  claim 12 , wherein the CDR is in the light chain. 
     
     
         23 . The humanized antibody of  claim 22 , wherein the amino acid sequence of CDR1 has at least 90% sequence identity to CDR1 (amino acids 24 to 34 of SEQ ID NO: 5) of MH9A3. 
     
     
         24 . The humanized antibody of  claim 23 , wherein the amino acid sequence of CDR1 comprises amino acids 24 to 34 of SEQ ID NO: 5. 
     
     
         25 . The humanized antibody of  claim 23 , wherein the amino acid sequence of CDR1 consists of amino acids 24 to 34 of SEQ ID NO: 5. 
     
     
         26 . The humanized antibody of  claim 22 , wherein the amino acid sequence of CDR2 comprises amino acids 50 to 56 of SEQ ID NO: 5. 
     
     
         27 . The humanized antibody of  claim 13 , wherein the amino acid sequence of CDR2 consists of amino acids 50 to 56 of SEQ ID NO: 5. 
     
     
         28 . The humanized antibody of  claim 22 , wherein the amino acid sequence of CDR3 has at least 85% sequence identity to CDR1 (amino acids 89 to 97 of SEQ ID NO: 5) of MH9A3. 
     
     
         29 . The humanized antibody of  claim 28 , wherein the amino acid sequence of CDR3 comprises amino acids 89 to 97 of SEQ ID NO: 5. 
     
     
         30 . The humanized antibody of  claim 28 , wherein the amino acid sequence of CDR3 consists of amino acids 89 to 97 of SEQ ID NO: 5. 
     
     
         31 . A humanized antibody which specifically binds to human IL-9 comprising:
 i. a variable heavy chain containing a CDR2 and CDR3 with an amino acid sequence with at least 90% sequence identity to CDR2 (amino acids 50 to 66 of SEQ ID NO: 3) and CDR3 (amino acids 50 to 66 of SEQ ID NO: 3) of MH9A3 heavy chain; and   ii. a variable light chain containing a CDR1 with an amino acid sequence with at least 90% sequence identity to CDR1 (amino acids 24 to 34 of SEQ ID NO: 5) of MH9A3 light chain.